# US 2012/0083442 A1 · Myostatin binding agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083442 A1
- Document ID: US20120083442A1
- Status: Published application
- Kind: A1
- Application number: 13/310,661
- Filed: 2011-12-02
- Published: 2012-04-05
- Earliest claimed: 2002-12-20
- Assignees: Amgen Inc.
- Inventors: HQ HAN; HOSUNG MIN; THOMAS CHARLES BOONE
- Web page: https://patentgrep.com/patent/US20120083442A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/475: Growth factors; Growth regulators
- G01N 33/567: utilising isolate of tissue or organ as binding agent
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- G01N 2333/475: Assays involving growth factors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

## Claims

### Claim 1

A binding agent comprising at least one peptide capable of binding myostatin, wherein the peptide comprises the amino acid sequence Ca1a2Wa3WMCPP (SEQ ID NO: 352), wherein a1, a2 and a3 are selected from a neutral hydrophobic, neutral polar, or basic amino acid, and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.

### Claim 2

A binding agent comprising at least one peptide capable of binding myostatin, wherein the peptide comprises the sequence Cb1b2Wb3WMCPP (SEQ ID NO: 353), wherein
b1 is selected from any one of the amino acids T, I, or R;
b2 is selected from any one of R, S, Q;
b3 is selected from any one of P, R and Q,
and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.

### Claim 3

A binding agent comprising at least one peptide capable of binding myostatin, wherein the peptide is selected from the group consisting of:
(a) a peptide comprising the amino acid sequence WYe1e2Ye3G, (SEQ ID NO: 356), wherein e1 is P, S or Y, e2 is C or Q, and e3 is G or H;
(b) a peptide comprising the amino acid sequence f1EMLf2SLf3f4LL, (SEQ ID NO: 455), wherein f1 is M or I, f2 is any amino acid, f3 is L or F, and f4 is E, Q or D;
(c) a peptide comprising the amino acid sequence Lg1g2LLg3g4L, (SEQ ID NO: 456), wherein g1 is Q, D or E, g2 is S, Q, D or E, g3 is any amino acid, and g4 is L, W, F, or Y; and
(d) a peptide comprising the amino acid sequence h1h2h3h4h5h6h7h8h6 (SEQ ID NO: 457), wherein h1 is R or D, h2 is any amino acid, h3 is A, T S or Q, h4 is L or M, h5 is L or S, h6 is any amino acid, h7 is F or E, h8 is W, F or C, and h9 is L, F, M or K,
and physiologically acceptable salts thereof.

### Claim 4

A binding agent wherein said agent has the structure:
(X1)a—F1—(X2)b, or multimers thereof;
wherein F1 is a vehicle; and X1 and X2 are each independently selected from
-(L1)c-P1;
-(L1)c-P1-(L2)d-P2;
-(L1)c-P1-(L2)d-P2-(L3)e-P3;
and -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4;
wherein P1, P2, P3, and P4 are peptides capable of binding myostatin, wherein L1, L2, L3, and L4 are each linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1, and physiologically acceptable salts thereof.

### Claim 5 (depends on 4)

The binding agent of claim 4 wherein one or more of the myostatin binding peptides comprise the amino acid sequence Ca1a2Wa3WMCPP (SEQ ID NO: 352), wherein a1, a2 and a3 are selected from a neutral hydrophobic, neutral polar, or basic amino acid, and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.

### Claim 6 (depends on 4)

The binding agent of claim 4, wherein one or more of the myostatin binding peptides comprise the amino acid sequence Cb1b2Wb3WMCPP (SEQ ID NO: 353), wherein
b1 is selected from any one of the amino acids T, I, or R;
b2 is selected from any one of R, S, Q;
b3 is selected from any one of P, R and Q,
and wherein the peptide is between 10 and 50 amino acids in length, and physiologically acceptable salts thereof.

### Claim 7 (depends on 4)

The binding agent of claim 4, wherein the myostatin binding peptides P1, P2, P3, and P4 are selected from the group consisting of:
(a) a peptide comprising the amino acid sequence WYe1e2Ye3G, (SEQ ID NO: 356), wherein e1 is P, S or Y, e2 is C or Q, and e3 is G or H;
(b) a peptide comprising the amino acid sequence f1EMLf2SLf3f4LL, (SEQ ID NO: 455), wherein f1 is M or I, f2 is any amino acid, f3 is L or F, and f4 is E, Q or D;
(c) a peptide comprising the amino acid sequence Lg1g2LLg3g4L, (SEQ ID NO: 456), wherein g1 is Q, D or E, g2 is S, Q, D or E, g3 is any amino acid, and g4 is L, W, F, or Y; and
(d) a peptide comprising the amino acid sequence h1h2h3h4h5h6h7h8h9 (SEQ ID NO: 457), wherein h1 is R or D, h2 is any amino acid, h3 is A, T S or Q, h4 is L or M, h5 is L or S, h6 is any amino acid, h7 is F or E, h8 is W, F or C, and h9 is L, F, M or K;
wherein the peptide is between 9 and 50 amino acids in length,
wherein L1, L2, L3, and L4 are each linkers; and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1, and physiologically acceptable salts thereof

### Claim 8

A binding agent wherein said agent has the structure:
(X1)a—F1—(X2)b, or multimers thereof
wherein F1 is a vehicle; and X1 and X2 are each independently selected from
-(L1)c-P1;
-(L1)c-P1-(L2)d-P2;
-(L1)c-P1-(L2)d-P2-(L3)e-P3;
and -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4;
wherein P1, P2, P3, and P4 are peptides capable of binding myostatin, and are independently selected from SEQ ID NO: 305 through 351 and SEQ ID NO: 357 through 454;
wherein L1, L2, L3, and L4 are each linkers;
and a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1, and physiologically acceptable salts thereof.

### Claim 9 (depends on 8)

The binding agent of claim 8, wherein the binding agent has the structure F1-(L1)c-P1 or F1-(L1)c-P1-(L2)d-P2.

### Claim 10 (depends on 9)

The binding agent of claim 9, wherein the peptide is selected from any one of SEQ ID NO: 305-308, 310-313, 315-331, 333, 335-346, wherein F1 is an Fc domain.

### Claim 11

A binding agent capable of binding myostatin comprising the structure F1-(L1)-P1, wherein F1 is a human IgG Fc, wherein L1 is (Gly)5, wherein the binding agent further comprises AQ and wherein P1 is selected from SEQ ID NO: 311, SEQ ID NO: 325, SEQ ID NO: 326, SEQ ID NO: 336, SEQ ID NO: 337, and SEQ ID NO: 345.

### Claim 12 (depends on 6)

A pharmaceutical composition comprising a therapeutically effective amount of the binding agent of claim 6 in admixture with a pharmaceutically acceptable carrier thereof.

### Claim 13 (depends on 6, 8)

An isolated nucleic acid molecule comprising a polynucleotide encoding the binding agent of any one of claim 6 or 8.

### Claim 14 (depends on 13)

The nucleic acid molecule of claim 13, wherein the polynucleotide selected from any one of SEQ ID NO: 573 through 614, and 616, 618, 620, 622, 624, 626, 628, 630, 632.

### Claim 15 (depends on 13)

An expression vector comprising the polynucleotide of claim 13.

### Claim 16 (depends on 15)

A host cell comprising the expression vector of claim 15.

### Claim 17 (depends on 16)

A method of making a myostatin binding agent comprising culturing the host cell of claim 16 under conditions suitable for expressing the binding agent, and purifying the binding agent.

### Claim 18 (depends on 12)

A method of inhibiting myostatin activity in a subject comprising administering an effective amount of the composition of claim 12 to the subject.

### Claim 19 (depends on 12)

A method of increasing lean muscle mass in a subject comprising administering the composition of claim 12 to the subject.

### Claim 20 (depends on 12)

A method of increasing the ratio of lean muscle mass to fat in a subject comprising administering a therapeutically effective amount of the composition of claim 12 to the subject.

### Claim 21 (depends on 12)

A method of treating a muscle-wasting disease in a subject comprising administering a therapeutically effective amount of the composition of claim 12 to the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the disease is selected from muscular dystrophy, amyotrophic lateral sclerosis, congestive obstructive pulmonary disease, chronic heart failure, cancer, AIDs, renal failure, uremia, rheumatoid arthritis, age-related sarcopenia, and muscle-wasting due to prolonged bedrest, spinal chord injury, stroke, bone fracture, and aging.

### Claim 23 (depends on 12)

A method of treating a myostatin-related metabolic disorder in a subject comprising administering a therapeutically effective amount of the composition of claim 12 to the subject.

### Claim 24 (depends on 23)

The method of claim 23 wherein the metabolic disorder is selected from diabetes, obesity, hyperglycemia, and bone loss.

### Claim 25 (depends on 1)

A method of detecting or measuring myostatin in a sample comprising contacting the sample with a binding agent of claim 1 and detecting or measuring the bound complex.
